The estimated Net Worth of Steven Weber is at least $326 Tausend dollars as of 14 June 2024. Mr Weber owns over 495 units of Aeglea BioTherapeutics Inc stock worth over $312,404 and over the last 4 years he sold AGLE stock worth over $13,692.
Mr has made over 2 trades of the Aeglea BioTherapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 495 units of AGLE stock worth $3,752 on 14 June 2024.
The largest trade he's ever made was selling 993 units of Aeglea BioTherapeutics Inc stock on 13 March 2024 worth over $9,940. On average, Mr trades about 248 units every 16 days since 2021. As of 14 June 2024 he still owns at least 26,012 units of Aeglea BioTherapeutics Inc stock.
You can see the complete history of Mr Weber stock trades at the bottom of the page.
Steven Weber is the VP, Principal Accounting Officer & Corp. Controller at Aeglea BioTherapeutics Inc.
Mr Weber is 44, he's been the VP und Principal Accounting Officer & Corp. Controller of Aeglea BioTherapeutics Inc since . There are 14 older and 1 younger executives at Aeglea BioTherapeutics Inc. The oldest executive at Aeglea BioTherapeutics Inc is V. Bryan Lawlis, 68, who is the Independent Director.
Steven's mailing address filed with the SEC is C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA, 94043.
Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... und Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include: